Gargoyle Investment Advisor’s Emergent Biosolutions EBS Stock Holding History

Gargoyle Investment Advisor’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,632	Closed	-$335K	–	189
2016 Q3	$335K	Hold	10,632	–	–	0.13%	167
2016 Q2	$299K	Sell	10,632 -3,600	-25%	-$141K	0.11%	179
2016 Q1	$517K	Buy	14,232 +634	+5%	+$22.4K	0.17%	167
2015 Q4	$544K	Buy	+13,598	New	+$474K	0.22%	128
2015 Q3	–	Sell	-15,299	Closed	-$504K	–	167
2015 Q2	$504K	Buy	+15,299	New	+$474K	0.19%	145
2013 Q4	–	Sell	-29,539	Closed	-$563K	–	129
2013 Q3	$563K	Buy	+29,539	New	+$527K	0.35%	68

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Gargoyle Investment Advisor's EBS Position: Q4 2016 in Review

Gargoyle Investment Advisor sold out of Emergent Biosolutions (EBS) in Q4 2016, closing a stake of 10,632 shares — an estimated $335K sold.

Gargoyle Investment Advisor first reported a position in EBS in Q3 2013 and held it in 6 quarters. The position peaked at $563K in Q3 2013. 208 funds tracked by Wall St. Rank hold EBS as of Q4 2016.

Gargoyle Investment Advisor reported no remaining Emergent Biosolutions position as of Q4 2016 after selling out during the quarter.
Gargoyle Investment Advisor sold 10,632 Emergent Biosolutions shares in Q4 2016, an estimated $335K.
Gargoyle Investment Advisor first reported a position in Emergent Biosolutions in Q3 2013 and held it in 6 quarters.
Gargoyle Investment Advisor's Emergent Biosolutions position peaked at $563K in Q3 2013.
208 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2016.

Based on Gargoyle Investment Advisor's 13F filing for Q4 2016, filed 27 Jan 2017.